Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $244.32 +1.99%
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +15.3%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $1.84, $0.24 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.32 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.2-4.5 billion, versus the consensus of $5.61 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Brookfield prices $600M senior notes at 5.65% due 2031
- GM Defense wins $697.7 million Army contract modification
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
